

PE/Cy7 anti-human HLA-DR

Catalog # / 2408055 / 25 tests
Size: 2408060 / 100 tests

Clone: Tü36

Isotype: Mouse IgG2b, κ


Immunogen: Human PBL

Reactivity: Human, Non-human primate, Other

Preparation: The antibody was purified by affinity chromatography and conjugated with PE/Cy7 under optimal conditions. The solution is free of unconjugated PE/Cy7 and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

Concentration: Lot-specific



Human peripheral blood monocytes were stained with HLA-DR (Clone Tü36) PE/Cy7 (filled histogram) or mouse IgG2b, κ PE/Cy7 isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 μ l per million cells in 100 μ l staining volume or 5 μ l per 100 μ l of whole blood.

Application Notes: Additional reported applications (of relevant formats) includes Western blotting⁴, immunoprecipitation⁴, and *in vitro* blocking⁵.

Application References:

1. Thorsby E. 1974. *Transplant. Rev.* 18:51.
2. Qvigstad E, *et al.* 1984. *Hum. Immunol.* 11:207.
3. Serenius B, *et al.* 1984. *EMBO J.* 3:3209.
4. Ottenhoff TH, *et al.* 1985. *Hum. Immunol.* 13:105.
5. Strassmann G, *et al.* 1985. *Hum. Immunol.* 13:125.
6. Trowsdale J, *et al.* 1985. *Immunol. Rev.* 85:5.

Description: HLA-DR is a heterodimeric cell surface glycoprotein comprised of an α (heavy) chain and a β (light) chain. They are expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells, and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. Variations in the HLA gene expression are crucial to graft survival.

Antigen References:

1. Thorsby E. 1974. *Transplant. Rev.* 18:51.
2. Qvigstad E, *et al.* 1984. *Hum. Immunol.* 11:207.
3. Serenius B, *et al.* 1984. *EMBO J.* 3:3209.
4. Ottenhoff TH, *et al.* 1985. *Hum. Immunol.* 13:105.
5. Strassmann G, *et al.* 1985. *Hum. Immunol.* 13:125.
6. Trowsdale J, *et al.* 1985. *Immunol. Rev.* 85:5.